Abivax Secures $920 Million to Push U. S. Launch of Bowel Disease Drug
Abivax, a French biotech firm working on a bowel disease treatment, recently raised $920 million in new funding. The cash boost gives the company a runway that stretches to the end of 2029. With these funds, Abivax plans to build the necessary infrastructure for a U. S. launch of its main drug